Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer

Inclusion criteria

• . Patients with progressive castration-resistant prostate cancer who meet the following conditions (1) and (2) (1) Patients with progressive increase of serum Prostate-Specific Antigen (PSA) (\>=2ng/mL, three consecutive increases at least one week apart, and two increases of more than 50% from the lowest value), or with the tumor growth or appearance of new lesions detected by imaging studies (2) Patients with the serum testosterone at castration level (\< 50ng/dL)
• . Patients who meet the following conditions (1) and (2), resistant to standard treatment or not indicated for the generally approved standard treatments (1) Patients who have received at least one of the following treatments
• . Patients aged 18 years or older at the time of consent acquisition
• . Patients with stable general condition with PS (Performance status) of 0 to 2 in ECOG (Eastern Cooperative Oncology Group)
• . Patients who can be expected to survive for 6 months or more, judging from clinical symptoms and medical examination findings
• . Patients without or with controlled symptomatic brain metastases
• . Patients with no clinically significant abnormal findings in electrocardiogram, respiratory rate, and blood oxygen saturation within 30 days before the enrollment
• . Patients whose laboratory values within 30 days before the enrollment are within the range specified in the protocol

Exclusion criteria